Bordetella pertussis toxin
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
1999
- First approval year
- 1999
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Bordetella pertussis toxin
- bordetella pertussis toxin component of triacelluvax
- Bordetella pertussis toxin component of triacelluvax
- bordetella pertussis toxin
- Bordetella pertussis toxin
- ChEMBL ID
- CHEMBL6068349
- First in class
- No
- Orphan designation
- No
- Mechanism
- Pertussis toxin vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Pertussis toxin
- Protein identifier
- P04977
- Mechanism
- Pertussis toxin vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Pertussis toxin
- Protein identifier
- P04978
- Mechanism
- Pertussis toxin vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Pertussis toxin
- Protein identifier
- P04979
- Mechanism
- Pertussis toxin vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Pertussis toxin
- Protein identifier
- P04981
- Mechanism
- Pertussis toxin vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Pertussis toxin
- Protein identifier
- P0A3R5
Open Targets mechanisms
- Mechanism
- Pertussis toxin vaccine antigen
- Action type
- VACCINE ANTIGEN
- Target
- Pertussis toxin
- Condition
- Whooping Cough
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000650
- Subject identifier
- D014917
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition identifier
- EFO_0000650
- Condition identifier
- MONDO_0005077
- Highest recorded phase
- 4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (45)
- 2-year Follow-up After a Single Dose Acellular Pertussis Vaccination
- 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age
- A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)
- A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
- A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
- A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants
- A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)
- A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years
- A Study to Assess the Safety of Adacel® Vaccine
- A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age
- A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
- Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
- Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants
- Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine
- Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine
- Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects
- Gambia Pertussis Study (GaPs)
- GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age
- Heterologous Effect of Diptheria, Tetanus, Acellular Pertussis Vaccination on Influenza Challenge in the Elderly
- Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines